{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T01:32:43Z","timestamp":1789522363040,"version":"build-2803163510"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2020,6,2]],"date-time":"2020-06-02T00:00:00Z","timestamp":1591056000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,6,2]],"date-time":"2020-06-02T00:00:00Z","timestamp":1591056000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/100001006","name":"Breast Cancer Research Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001006","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004334","name":"Merck","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004334","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005294","name":"Massachusetts General Hospital","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005294","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute","doi-asserted-by":"publisher","award":["1R01CA227156-01"],"award-info":[{"award-number":["1R01CA227156-01"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute","doi-asserted-by":"publisher","award":["5R21CA220253-02"],"award-info":[{"award-number":["5R21CA220253-02"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute","doi-asserted-by":"publisher","award":["1R01CA244975-01"],"award-info":[{"award-number":["1R01CA244975-01"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute","doi-asserted-by":"publisher","award":["1R01CA244975-01"],"award-info":[{"award-number":["1R01CA244975-01"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute","doi-asserted-by":"publisher","award":["1R01CA244975-01"],"award-info":[{"award-number":["1R01CA244975-01"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute","doi-asserted-by":"publisher","award":["5R21CA220253-02"],"award-info":[{"award-number":["5R21CA220253-02"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute","doi-asserted-by":"publisher","award":["1R01CA227156-01"],"award-info":[{"award-number":["1R01CA227156-01"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001021","name":"Damon Runyon Cancer Research Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001021","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005190","name":"Melanoma Research Alliance","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005190","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001453","name":"American Brain Tumor Association","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001453","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Med"],"published-print":{"date-parts":[[2020,8,1]]},"DOI":"10.1038\/s41591-020-0918-0","type":"journal-article","created":{"date-parts":[[2020,6,1]],"date-time":"2020-06-01T12:03:55Z","timestamp":1591013035000},"page":"1280-1284","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":136,"title":["Single-arm, open-label phase 2 trial of pembrolizumab in patients with leptomeningeal carcinomatosis"],"prefix":"10.1038","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4470-8425","authenticated-orcid":false,"given":"Priscilla K.","family":"Brastianos","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eudocia Quant","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Justine V.","family":"Cohen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara M.","family":"Tolaney","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nancy U.","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nancy","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ugonma","family":"Chukwueke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3855-9243","authenticated-orcid":false,"given":"Michael D.","family":"White","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naema","family":"Nayyar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Albert","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher","family":"Alvarez-Breckenridge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ian","family":"Krop","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maura Keeley","family":"Mahar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mia S.","family":"Bertalan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian","family":"Shaw","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joana L.","family":"Mora","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathaniel","family":"Goss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Megha","family":"Subramanian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lakshmi","family":"Nayak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jorg","family":"Dietrich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deborah A.","family":"Forst","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian V.","family":"Nahed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tracy T.","family":"Batchelor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helen A.","family":"Shih","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth R.","family":"Gerstner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beverly","family":"Moy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donald","family":"Lawrence","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anita","family":"Giobbie-Hurder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8480-1475","authenticated-orcid":false,"given":"Scott L.","family":"Carter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin","family":"Oh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel P.","family":"Cahill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5344-6645","authenticated-orcid":false,"given":"Ryan J.","family":"Sullivan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,6,2]]},"reference":[{"key":"918_CR1","doi-asserted-by":"crossref","unstructured":"Brastianos, P.K., Brastianos, H. & Eichler, A.F. Leptomeningeal carcinomatosis. in Central Nervous System Metastasis, the Biological Basis and Clinical Consideraiton (ed. Palmieri, D.) 187\u2013201 (Springer, 2013).","DOI":"10.1007\/978-94-007-5291-7_10"},{"key":"918_CR2","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1007\/s11060-017-2452-6","volume":"133","author":"E Le Rhun","year":"2017","unstructured":"Le Rhun, E. et al. Diagnosis and treatment patterns for patients with leptomeningeal metastasis from solid tumors across Europe. J. Neurooncol. 133, 419\u2013427 (2017).","journal-title":"J. Neurooncol."},{"key":"918_CR3","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1002\/cncr.30911","volume":"124","author":"N Wang","year":"2018","unstructured":"Wang, N., Bertalan, M. S. & Brastianos, P. K. Leptomeningeal metastasis from systemic cancer: review and update on management. Cancer 124, 21\u201335 (2018).","journal-title":"Cancer"},{"key":"918_CR4","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1200\/JCO.1993.11.3.561","volume":"11","author":"SA Grossman","year":"1993","unstructured":"Grossman, S. A. et al. Randomized prospective comparison of intraventricular methotrexate and thiotepa in patients with previously untreated neoplastic meningitis. Eastern Cooperative Oncology Group. J. Clin. Oncol. 11, 561\u2013569 (1993).","journal-title":"J. Clin. Oncol."},{"key":"918_CR5","doi-asserted-by":"publisher","first-page":"1565","DOI":"10.1212\/WNL.33.12.1565","volume":"33","author":"BW Ongerboer de Visser","year":"1983","unstructured":"Ongerboer de Visser, B. W. et al. Intraventricular methotrexate therapy of leptomeningeal metastasis from breast carcinoma. Neurology 33, 1565\u20131572 (1983).","journal-title":"Neurology"},{"key":"918_CR6","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1053\/ctrv.1999.0119","volume":"25","author":"SA Grossman","year":"1999","unstructured":"Grossman, S. A. & Krabak, M. J. Leptomeningeal carcinomatosis. Cancer Treat. Rev. 25, 103\u2013119 (1999).","journal-title":"Cancer Treat. Rev."},{"key":"918_CR7","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1001\/archneur.1974.00490320026003","volume":"30","author":"JR Little","year":"1974","unstructured":"Little, J. R., Dale, A. J. & Okazaki, H. Meningeal carcinomatosis. Clinical manifestations. Arch. Neurol. 30, 138\u2013143 (1974).","journal-title":"Arch. Neurol."},{"key":"918_CR8","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1111\/j.1524-4741.2012.01228.x","volume":"18","author":"F Lara-Medina","year":"2012","unstructured":"Lara-Medina, F. et al. Clinical features and prognostic factors in patients with carcinomatous meningitis secondary to breast cancer. Breast J. 18, 233\u2013241 (2012).","journal-title":"Breast J."},{"key":"918_CR9","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1007\/s11060-012-0880-x","volume":"109","author":"MC Chamberlain","year":"2012","unstructured":"Chamberlain, M. C. Neurotoxicity of intra-CSF liposomal cytarabine (DepoCyt) administered for the treatment of leptomeningeal metastases: a retrospective case series. J. Neurooncol. 109, 143\u2013148 (2012).","journal-title":"J. Neurooncol."},{"key":"918_CR10","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1016\/S0929-6646(08)60201-6","volume":"107","author":"TY Chuang","year":"2008","unstructured":"Chuang, T. Y., Yu, C. J., Shih, J. Y., Yang, P. C. & Kuo, S. H. Cytologically proven meningeal carcinomatosis in patients with lung cancer: clinical observation of 34 cases. J. Formos. Med. Assoc. 107, 851\u2013856 (2008).","journal-title":"J. Formos. Med. Assoc."},{"key":"918_CR11","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1007\/BF01806382","volume":"9","author":"G Clamon","year":"1987","unstructured":"Clamon, G. & Doebbeling, B. Meningeal carcinomatosis from breast cancer: spinal cord vs. brain involvement. Breast Cancer Res. Treat. 9, 213\u2013217 (1987).","journal-title":"Breast Cancer Res. Treat."},{"key":"918_CR12","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1136\/pgmj.56.653.149","volume":"56","author":"R Boyle","year":"1980","unstructured":"Boyle, R., Thomas, M. & Adams, J. H. Diffuse involvement of the leptomeninges by tumour\u2013a clinical and pathological study of 63 cases. Postgrad. Med. J. 56, 149\u2013158 (1980).","journal-title":"Postgrad. Med. J."},{"key":"918_CR13","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1097\/00005792-198201000-00005","volume":"61","author":"ST Rosen","year":"1982","unstructured":"Rosen, S. T. et al. Carcinomatous leptomeningitis in small cell lung cancer: a clinicopathologic review of the National Cancer Institute experience. Medicine 61, 45\u201353 (1982).","journal-title":"Medicine"},{"key":"918_CR14","doi-asserted-by":"publisher","first-page":"641","DOI":"10.3389\/fonc.2018.00641","volume":"8","author":"RA El Shafie","year":"2018","unstructured":"El Shafie, R. A. et al. Palliative radiotherapy for leptomeningeal carcinomatosis-analysis of outcome, prognostic factors, and symptom response. Front. Oncol. 8, 641 (2018).","journal-title":"Front. Oncol."},{"key":"918_CR15","first-page":"3394","volume":"5","author":"MJ Glantz","year":"1999","unstructured":"Glantz, M. J. et al. A randomized controlled trial comparing intrathecal sustained-release cytarabine (DepoCyt) to intrathecal methotrexate in patients with neoplastic meningitis from solid tumors. Clin. Cancer Res. 5, 3394\u20133402 (1999).","journal-title":"Clin. Cancer Res."},{"key":"918_CR16","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1016\/S1470-2045(18)30139-6","volume":"19","author":"GV Long","year":"2018","unstructured":"Long, G. V. et al. Combination nivolumab and ipilimumab or nivolumab alone in melanoma brain metastases: a multicentre randomised phase 2 study. Lancet Oncol. 19, 672\u2013681 (2018).","journal-title":"Lancet Oncol."},{"key":"918_CR17","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1016\/S1470-2045(12)70090-6","volume":"13","author":"K Margolin","year":"2012","unstructured":"Margolin, K. et al. Ipilimumab in patients with melanoma and brain metastases: an open-label, phase 2 trial. Lancet Oncol. 13, 459\u2013465 (2012).","journal-title":"Lancet Oncol."},{"key":"918_CR18","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1056\/NEJMoa1805453","volume":"379","author":"HA Tawbi","year":"2018","unstructured":"Tawbi, H. A. et al. Combined nivolumab and ipilimumab in melanoma metastatic to the brain. N. Engl. J. Med. 379, 722\u2013730 (2018).","journal-title":"N. Engl. J. Med."},{"key":"918_CR19","doi-asserted-by":"publisher","first-page":"976","DOI":"10.1016\/S1470-2045(16)30053-5","volume":"17","author":"SB Goldberg","year":"2016","unstructured":"Goldberg, S. B. et al. Pembrolizumab for patients with melanoma or non-small-cell lung cancer and untreated brain metastases: early analysis of a non-randomised, open-label, phase 2 trial. Lancet Oncol. 17, 976\u2013983 (2016).","journal-title":"Lancet Oncol."},{"key":"918_CR20","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1002\/1097-0142(19820215)49:4<759::AID-CNCR2820490427>3.0.CO;2-7","volume":"49","author":"WR Wasserstrom","year":"1982","unstructured":"Wasserstrom, W. R., Glass, J. P. & Posner, J. B. Diagnosis and treatment of leptomeningeal metastases from solid tumors: experience with 90 patients. Cancer 49, 759\u2013772 (1982).","journal-title":"Cancer"},{"key":"918_CR21","doi-asserted-by":"publisher","first-page":"e534","DOI":"10.1016\/S1470-2045(15)00088-1","volume":"16","author":"H Okada","year":"2015","unstructured":"Okada, H. et al. Immunotherapy response assessment in neuro-oncology: a report of the RANO working group. Lancet Oncol. 16, e534\u2013e542 (2015).","journal-title":"Lancet Oncol."},{"key":"918_CR22","doi-asserted-by":"publisher","first-page":"2108","DOI":"10.1056\/NEJMoa1809615","volume":"379","author":"P Schmid","year":"2018","unstructured":"Schmid, P. et al. Atezolizumab and nab-paclitaxel in advanced triple-negative breast cancer. N. Engl. J. Med. 379, 2108\u20132121 (2018).","journal-title":"N. Engl. J. Med."},{"key":"918_CR23","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1007\/s10549-017-4537-5","volume":"167","author":"LY Dirix","year":"2018","unstructured":"Dirix, L. Y. et al. Avelumab, an anti-PD-L1 antibody, in patients with locally advanced or metastatic breast cancer: a phase 1b JAVELIN Solid Tumor study. Breast Cancer Res. Treat. 167, 671\u2013686 (2018).","journal-title":"Breast Cancer Res. Treat."},{"key":"918_CR24","doi-asserted-by":"publisher","DOI":"10.1186\/s13058-016-0702-8","volume":"18","author":"R Duchnowska","year":"2016","unstructured":"Duchnowska, R. et al. Immune response in breast cancer brain metastases and their microenvironment: the role of the PD-1\/PD-L axis. Breast Cancer Res. 18, 43 (2016).","journal-title":"Breast Cancer Res."},{"key":"918_CR25","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1055\/s-0030-1255220","volume":"30","author":"MC Chamberlain","year":"2010","unstructured":"Chamberlain, M. C. Leptomeningeal metastasis. Semin. Neurol. 30, 236\u2013244 (2010).","journal-title":"Semin. Neurol."},{"key":"918_CR26","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1007\/s00066-011-0025-8","volume":"188","author":"C Gani","year":"2012","unstructured":"Gani, C. et al. Outcome after whole brain radiotherapy alone in intracranial leptomeningeal carcinomatosis from solid tumors. Strahlenther. Onkol. 188, 148\u2013153 (2012).","journal-title":"Strahlenther. Onkol."},{"key":"918_CR27","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1007\/s11060-008-9758-3","volume":"93","author":"F Waki","year":"2009","unstructured":"Waki, F. et al. Prognostic factors and clinical outcomes in patients with leptomeningeal metastasis from solid tumors. J. Neurooncol. 93, 205\u2013212 (2009).","journal-title":"J. Neurooncol."},{"key":"918_CR28","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1016\/j.ejca.2019.05.019","volume":"116","author":"LEL Hendriks","year":"2019","unstructured":"Hendriks, L. E. L. et al. Survival of patients with non-small cell lung cancer having leptomeningeal metastases treated with immune checkpoint inhibitors. Eur. J. Cancer 116, 182\u2013189 (2019).","journal-title":"Eur. J. Cancer"}],"updated-by":[{"DOI":"10.1038\/s41591-020-0978-1","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2020,6,18]],"date-time":"2020-06-18T00:00:00Z","timestamp":1592438400000}}],"container-title":["Nature Medicine"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/s41591-020-0918-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41591-020-0918-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41591-020-0918-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,20]],"date-time":"2023-05-20T18:03:20Z","timestamp":1684605800000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41591-020-0918-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6,2]]},"references-count":28,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2020,8,1]]}},"alternative-id":["918"],"URL":"https:\/\/doi.org\/10.1038\/s41591-020-0918-0","relation":{},"ISSN":["1078-8956","1546-170X"],"issn-type":[{"value":"1078-8956","type":"print"},{"value":"1546-170X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,6,2]]},"assertion":[{"value":"30 August 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 May 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 June 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 June 2020","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1038\/s41591-020-0978-1","URL":"https:\/\/doi.org\/10.1038\/s41591-020-0978-1","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"P.K.B. has consulted for Tesaro, Angiochem, Genentech-Roche, ElevateBio and Eli Lilly, has received institutional research funding (to Massachusetts General Hospital) from Merck, Eli Lilly, BMS and Pfizer and has received honoraria from Merck and Genentech-Roche. J.C. has received consulting fees from Sanofi-Genzyme and BMS. D.P.C. has consulted for Eli Lilly and Boston Pharmaceuticals and has received travel and speaking fees from Merck. S.M.T. receives institutional research funding from Novartis, Genentech, Eli Lilly, Pfizer, Merck, Exelixis, Eisai, Bristol Meyers Squibb, AstraZeneca, Cyclacel, Immunomedics, Odenate and Nektar. S.M.T. has served as an advisor and consultant to Novartis, Eli Lilly, Pfizer, Merck, AstraZeneca, Eisai, Puma, Genentech, Immunomedics, Nektar, Tesaro, Daiichi Sankyo, Athenex, Sanofi, Bristol Meyers Squibb and Nanostring. N.U.L. has received institutional research funding from Seattle Genetics, Genentech, Merck and Pfizer. N.U.L. has also served on an advistory board or consulted for PUMA Biotechnology, Seattle Genetics and Daichii Sankyo. R.J.S. has received research funding from Amgen and Merck and has served as a paid consultant and\/or been on an advisory board for Array BioPharma, Amgen, Asan Biosciences, BMS, Compugen, Genentech, Merck, Novartis and Replimmune. E.Q.L. has received royalties from Wolters Kluwers (UpToDate, Inc) and has consulted for Eli Lilly. B.M. has received institutional research funding from PUMA Biotechnology. D.A.F. is an Eli Lilly shareholder. I.K. has received personal fees for being a member of a Merck DSMC, has received research funding from Genentech and Pfizer and has served as a paid consultant and\/or been on an advisory board for Genentech, Bristol Meyers Squibb, Daiichi\/Sankyo, Macrogenics and AstraZeneca. T.T.B. is on the Scientific Advisory Board for Genomicare. M.D.W. is a consultant at Boston Pharmaceuticals. Dana-Farber Cancer Institute has a financial interest in pembrolizumab and has taken steps to manage any actual or potential conflict of interest created by this financial interest, which was described in the information sheet available to all participants in this study.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}